P:5/8 – Macrolides  by unknown
COndusion: Linezolid was 6-fold more active than vancomycin against
CNS and enterococci and 100fold more active than teicoplanin against CNS.
Linezolid was 2-fold more active than teicoplanin and vancomycin against
S. aureus. Linezolid is a promising drug to treat infections caused by Gram-
positive cocci.
thromycin (ERY), ampicillin (AMP) and other antibiotics against Gram-
positive micro-organisms. Strains were isolated fromJune 1999 untilJanuary
2000 from hospitalized and non-hospitalized (only for pneumococci)
patients with clinical significant infections. 1250 strains from blood.
sputum, pus and CSF were included. MICs were obtained with the Erest.
BHI agar and an inoculum of2.0 McFarland was used for staphylococci and
enterococci (glycopeptides only) to support a better growth and clear
recognition of hetero-resistant colonies. The NCCLS method was used
for all other testing. Results are expressed as below:
VAN TEl
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extension plays a key role in the enhanced ribosomal binding of TEL, this
group on its own is unable to interact with the 23S rRNA. It is possible that
ketolides such as TEL dock into domain V ofthe rRNA target guiding the
Cll,l2-alkyl/aryl extension into a position where it can make contact with
domain II.
p:sn - Linezolid
IWeP991/n vitro activity of Iinezolid against staphylococd
C. Cuny, W. Witte
Robert Koch Institute, Wernigerode, Branch, 38855 Wernigerode, Germany
Objective: To determine MIC profiles oflinezolid for MSSA, MRSA and
coagulase negative staphylococci.
Design: MSSA (n = 245) and MRSA (n = 58) and coagulase negative
staphylococci (n = 197) of different origin sent from all over Germany to
the national staphylococcal reference center were subjected to genomic
typing (Smal macrorcstriction pattern) and to in "itro susceptibility testing
by means 'of microbroth MIC. Mutant frequencies were determined by
plating of aliquots from broth cultures onto isosensitest agar containing 8
mg/l linezolid.
Results: MIC's for linezolid were in the range between 0.5 and 2.0 mg/I. It
was not possible to select in vitro mutants among 10111 cfu, also not for MRSA
obviously possessing mutator alleles (elevated mutant frequencies for rifs-+
rifr, tmp-s -+ tmp-r).
Conclusion: MSSA and MRSA belonging to different clonal groups of S.
aureus are sensitive to linozolid. Mutation to resistance is obviously a rare
event.
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IWeP100IA Pan-European multicentre susceptibility study
(PEMSS) of clinical isolates to llnezolid and other comparator
antibiotics
C. G. Gemmell
On behalfofcontributors to PEMSS; University ofGlasgow, United Kingdom
Medical School, Bacteriology Department
A Pan-European Multicentre Susceptibility Study tested a total of 3382
recently isolated bacterial clinical isolates which were associated with skin,
blood or respiratory tract infection. Isolates originated from France, Italy,
Germany, Spain, The Netherlands, Sweden and the United Kingdom.
Laboratories in each country independently conducted in vitro susceptibility
tests using National Committee for Clinical Laboratory Standards
(NCCLS) broth microdilution and E-test agar dilution methodology.
MIC values for each organism were determined and MIC50 and MIC90
values were calculated. The activity of Iinezolid was compared to that of
appropriate comparator agents. Linezolid demonstrated excellent activity
against all of the Gram-positive bacteria tested including methicillin-
resistant staphylococci, vancomycin-resistant enterococci and penicillin-
resistant pneumococci. Linezolid demonstrated only modest activity against
the Gram-negative respiratory tract pathogens Moraxella catarrhalis and
Haemophilus injluenzae. When the MIC data for all countries were com-
bined, the MIC50 and MIC90 values were comparable. Overall, the lowest
MIC values were obtained for isolates from Italy and the highest values were
for isolates from The Netherlands. Correlation of broth microdilutioD and
E-test MIC values indicated very similar results for vancomycin except for
VRE. Both methods indicated resistance but the MICs varied by 4-fold.
There was also little variation between MIC values for penicillin and
amoxicillin/clavulanic acid using the two methods. Linezolid E-test results
were generally lower than those obtained by the broth microdilution assay.
Overall, Iinezolid was highly active against European isolates of Gram-
positive bacteria consistent with the results of other global studies.
IWeP1011 Multi-center in vitro evaluation of Iinezolid
compared with other antibiotics in The Netherlands
A. R.Janszl,j. W. Mouton2
lpAMM Laboratory for Medical Microbiology, Veldhoven; 2Canisius
Wilhelmina Hospital, Nijmegen, Netherlands
35 Laboratories participated in a multi-ccntre study in The Netherlands to
assess the in vitro activity oflinezolid (LIN), vancomycin (VAN), teicopla-
Din (TEl), oxacillin (OXA), penicillin G (pEN), gentamicin (GEN), ery-
IWeP1 021 Susceptibility of gram-positive cocci from 25 UK
hospitals to Iinezolid and other antibiotics
C. Henwood. D. Livermore, A.Johnson, D.James. M. Warner
Linezolid Study Group; ARMRL, Colindale, London, United Kingdom
Objectives: To determine the prevalence of antibiotic resistance amongst
gram-positive cocci isolated in UK hospitals.
Methods: 25 geographically diverse UK hospitals collected consecutive,
clinically significant isolates comprising: 30 Staphylococcus aureus, 30 coagu-
lase negative staphylococci (CNS), 40 enterococci and 40 Streptoco«Us
pneumotliae. Isolates were tested using E-tests according to NCCLS criteria.
For quality control, 10% ofisolates plus those with unusual resistances were
re-tested centrally.
Results: The overall resistance rates to methicillin in S. aureus and CNS
were 19.5% and 68.9% respectively. MRSA rates in individual hospitals
ranged from 0-43.3%. Vancomycin resistance in enterococci was signifi-
cantly higher in Eltterococcus faecium (24.1 %) than E. faecalis (0.5%) (p <
0.05) with resistant isolates carrying the vanA gene. The overall resistance
rate to penicillin amongst pneumococci was 8.9%. This resistance was
predominantly intermediate resistance; with only 6 hospitals reporting
high level penicillin resistance in pneumococci. No resistance to linezolid
was found in any ofthe organisms tested; MICs for staphylococci were 0.06-
4 mg/L; for enterococci 0.12-4 mg/L and for pneumococci 0.12-4 mg/L.
Conclusions: Resistance to established antimicrobials is common in gram-
positive cocci in UK hospitals. Linezolid may prove a useful therapeutic
alternative.
P:5/8 - Macrolides
/WeP1031 Macrolide resistance in StTeptococcus pneumonlae
in Russia
T. Bogdanovitcht, L. Stratchounskil• P. Huovinen2
lSmolensk Medical Academy Smolensk, Russian Federation; 2National Public
Health Institute, Turku, Finlaltd
Objectives: To investigate the incidence and mechanisms of macrolide
resistance in clinical isolates of S. pneumoltiae
Methods: 111 clinical strains ofS. pneumoniae isolated during the 1999 were
studied. The MICs of erythromycin, azithromycin, spiramycin and cIin-
damycin were determined by the NCCLS agar dilution technique. All
erythromycin-resistant (ER) strains were further evaluated by PCR for the
presence of prm and mefgenes.
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Rewlts: Only 3.6% (4{111) of the tested strains were resistant to erythro-
mycin.
Results, "g/ml Breakpoints MICSO MIC90 Range %R
Erythromycin S ~ O.25R ~ 1 0.032 0.032 0.032- > 64 3.6
Azithromycin S ~ O.5R ~ 2 0.064 0.125 0.032- > 64 3.6
Spiramycin n/a 0.125 0.125 0.032- > 64
Clindamycin S ~ 0.25R;::: 1 0.032 0.064 0.008- > 64 0.9
One ER strain showed constitutive resistance to all studied macrolides and
clindamycin (MICs > 64 I£gfml). suggesting an MLSB phenotype, and
carried the ermB gene. The remaining 3 isolates had classical M-phenotype
by double disc test. low-level resistance to 14- and IS-membered macrolide
(MICs, 8-16I£g{rnl) and were susceptible to 16-membered macrolide (MIC
spiramycin. 0.125I£g{rnl) and clindamycin (MIC. 0.32I£g{rnl). All of these
strains possessed mejE gene.
Conclusion: The resistance rate of S. pneumoniae to macrolides is still
relatively low in Russia with the M-phenotype being the most predomi-
nant. However because to our knowledge this is the first repon on
macrolide-resistance in pneumococci in Russia and taking in to account
the increasing prevalence ofER S. pneumoniae in other countries. continuing
surveillance of macrolide resistance in S. pneumoniae is advisable.
IWeP1041 Evolution of resistances towards macrolides in S.
pyogenes during '90 years
D. Crottil , C. RossettiZ, M. C. Medoril
1Microbiology; 2pediatry. Azienda Ospedaliera di Perugia. Italy
Objectives: To value the evolution of resistance towards erythromycin
(ER), azithromycin (AZ) and rokitamycin (RO) in Streptococcus pyogenes.
Methods: Since 1993 until 1999 we tested 2470 strains of Streptococcus
pyogenes versus ER, AZ and RO, using modified agar diffusion system, as
recommended.
Rewlts: Total sensitivities were: ER 72.2%, AZ 76.9%, RO 95.2%. The
true resistances to ER increased from 4.0% in 1993, to 34.7% in 1998 and
26.8% in 1999; to AZ increased from 4.0% in 1993 to 32.9% in 1997 and to
29.9% in 1998; to RO increased from 0.4% in 1996 to 7.0% in 1999 and
3.1 % in 1999.
Condusions: It is difficult to understand the evident increase ofresistance to
14 and 15 atoms macrolides, not only probably cause by exclusive use of
these antibiotics. Anyway, the sensitivity test is mandatory and the choice is
secondary to "in vitro" results, so the therapy will be aimed and efficacious.
RO seems a good drug, as bt:ta-Iactamics, on the base oflaboratory tests
and clinical evidence and availability.
IWeP1OS[ Oarlthromycin mediated expression of PMN
response against S. pneumoniae
A. M. Cuffini, V. Tullio, N. Mandras, N. Bianchi,J. Roana, D. Scalas, N.
A. Carlone
Dept. Public Health alld Microbiology, University of Turin, Italy
Objectives: Because of the rising prevalence of resistance to penicillin in S.
pneumoniae worldwide, the choice ofantimicrobial therapy must be carefully
considered and leads to a need for therapeutic alternatives. Taking into
account that the clinical response to treatment is usually a function of
multiple factors, i.e. the combined effect of antibiotics and host defence
mechanisms, we have studied the influence of c1arithromycin upon the
interaction between human polymorphonuclear granulocytes (PMNs) and
several strains of S. pneumoniae (penicillin-S, penicillin-R, penicillin and
c1arithromycin-R strains).
Methods: PMNs were collected from normal volunteers. The influence of
c1arithromycin upon the phagocytosis and intracellular killing have been
evaluated: the phagocytosis was determined by using 3H-radiolabelled
streptococci and the microbicidal activity was expressed as the survival
index.
Results: Clarithromycin appears to have some interesting immunomodify-
ing properties: it is able to influence the host-bacteria interaction resulting in
a considerable enhancement of human PMN functions, particularly the
intracellular microbicidal activity against all the strains of S. pneumoniae
tested.
Condusions: From these results it emerges that c1arithromycin is likely to
offer prescribers an advantageous alternative over currently available thera-
pies in the treatment of respiratory tract infections substained by S.
pneumoniae, included the penicillin-resistant ones.
IWeP1061 Macrolide-resistant Streptococcus pneumoniae and
antimicrobial consumption
M. Pihlajamakil,J.jalava, T. Kaurila, T. Klaukka, E. Paiva, P. Kotilainen.
P. Huovinen
The Finnish Study Group for Antimicrobial Resistance; I National Public Health
Institute, Turku, Finland
Objectives: To define a connection between antimicrobial consumption
and resistant pneumococci.
Methods: In 1997, a total of 6106 pneumococcal isolates were studied in
Finland in 22 clinical microbiology laboratories. These isolates account for
more than 95% of all pneumococci isolated annually in the entire country.
Most of the pneumococci were collected from the upper respiratory tract,
8% were blood culture isolates and 0.5% from CNS -samples. The routine
susceptibility testing was performed to penicillin (22 laboratories), erythro-
mycin (15), clindamycin (12), sulfatrimethoprim (11) and tetracycline (8) by
disc diffusion following the NCCLS guidelines. Data on the exact regional
use of antibiotics was obtained from the National Agency of Medicines. In
this study, the regional resistance levels of pneumococci in 1997 were
compared to the antimicrobial usage rates of the two previous years,
1995-1996. To evaluate the significance, Spearman's non-parametric corre-
lation analysis was used.
Results: The macrolide resistance ofpneumococci varied regionally from 2
to 12%. Resistance correlated highly significantly with macrolide (p =
0.007), beta-Iactam (p = 0.006) and total out-patient antibacterial use (p =
0.001) in these regions. In addition, a significant correlation was found
between sulfatrimethoprim resistance and sulfa-trimethoprim (p = 0.043)
and beta-Iactam use (p = 0.033). Interestingly, there was no correlation
between penicillin resistance and use of any ofthe antibacterial groups. This
may be explained by the low level of penicillin-resistant pneumococci.
Conduslons: In this study, a highly significant correlation was found
between antibiotic consumption and occurrence of macrolide-resistant
pneumococci.
IWeP1071 The Alexander Project 1998 - Susceptibility of
community-acquired LRTI isolates of Sfteptococcus pneumoniae
to mauolide and Iincosamide antibiotics
D. Felminghaml , M. R.jacobsZ, P. C. Appelbaum3
71,e Alexander Project Group; 'GR Micro Ltd., London, United Kingdom;
2Case Western Reserve University, Cleveland, OR; JRershey Medil:al Centre,
Hershey, PA, United States
Objectives: The Alexander Project was established in 1992 as a longitudinal
study of the antimicrobial susceptibility of community-acquired, bacterial
lower respiratory tract pathogens from geographically separated centres in
the US and the EU, and has now been extended to include all five continents.
Methods: MICs ofbacterial isolates collected in the study were determined
by microbroth dilution using standard NCCLS methods, and interpreted
using breakpoints also published by the NCCLS.
Results: In 1998, 4012 isolates of S. pneumoniae were tested. Macrolide
resistance was 28% overall in 1998, with values for erythromycin, clari-
thromycin and azithromycin being almost identical. For S. pneumoniae
isolates tested from Hong Kong, japan, Singapore, France, Belgium, Italy,
Mexico, Saudi Arabia and the US macrolide resistance exceeded 30%.
Macrolide resistance continues to evolve in association with penicillin
resistance in most countries. However, macrolide resistance was particularly
prevalent amongst penicillin-susceptible isolates in japan (50.6%), Italy
(39.6%). Hong Kong (36.8%). Belgium (33.7%) and Singapore (22%)
whilst rates oflG-20% were found in France (12.8%), Switzerland (12.7%)
and the UK (10%). The pattern of clindamycin resistance in comparison
with macrolide resistance reflected th" prevalences of ribosomal methylase
(dominant in 12 of the 24 countries included) versus efflux macrolide
resistance mechanisms.
Condusions: These data emphasise the increasing problem of resistance to
the macrolides amongst isolates of S. pneumoniae throughout the world in
both penicillin-susceptible and -resistant isolates.
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[WeP1081 Resistance to macrolides in a group A Streptococci
in pharyingeous samples
The phenotype pattern resistance ofthe 55 strains studied was: constitutive
resistance 5.45%, inducible resistance 27.27% and M phenotype 67.27%. In
M phenotype (38 strains) we tested CMI to erythromycin (> 4). clinda-
mycin ( < = 0.5) and josamycin ( < 0.03-0.06, 91.89% and < 0.125-0.25,
8.10%). A sensibility correlation between clindamycin and josamycin was
observed.
COndusions: Due to the high percentage of resistance in our area, it is
necessary to test erythromycin resistance in group A Streptococci and to
know the prevalence ofM phenotype because ofits importance in the choice
of an appropriate antibiotic therapy in the clinical practice.
P. Liendo, M.J. Unzaga, P. Velasco, M. B. Amezua. R. Cisterna
CIi,lical Microbiology and Infection Control Department, Hospital de BaSlIrlO,
Osakidetza, Bilbao, Spain
Objectives: Knowledge of the incidence oferythromycin resistant in group
A Streptococci in pharyingeous sampl~ from t995 to t999. We also studied
the models of macrolides resistance in the strains resistant to erythromycin
fTOm October of t998 to December of 1999.
Methods: We carried out a retrospective study of group A Streptococci
isolated in the Hospital of Basurto between 1995 and 1999. The Hospital of
Basurto is a 800 bed primary and tertiary care, teaching hospital that
provides care in the urban area of Bilbao (Spain). In our study of the
phenotype pattern of erythromycin-clindamycin resistance a double-disk
test was used.
Results: Erythromycin resistance in the different years:
IWeP110IPrevalence. phenotypes and genetics of macrolide-
resistant S. pyogenes in Austria
C. Jebelean!, I. Krieberneg~2, G. Feierl2, A. Bocksrucker·, R.
Watschingerl , M. Haditsch , L. Binder·, H. Mittermayer1
IElisabethinerr Hospital Linz; 2Karl Franzerrs Univ. Graz, Austria
Objectives: to investigate the prevalence, phenotypes and genetics of
macrolide-resistant S. pyogenes in Austria.
Materials and Methods: We began to monitor thc susceptibility of S.
pyogene5 strains in our institution in 1994. During 1999 we also collected
strains from other regions in Au.~tria. 323 strains were examined using the
agar dilution method on Mueller-Hinton agar supplemented with 5% sheep
blood for susceptibility to erythromycin (E), tetracycline (T) and clinda-
mycin (CI). 145 strains were also examined for azithromycin (An), clari-
thromycin (Cia), roxithromycin (Ro) and josamycin susccptibility. We
determined the macrolide resistance phenotype using a double-disk test with
E and CI. We used a PCR method to detect we the presence of mefA,
ermAM and ermTR genes.
Results: The prevalence ofantibiotic resistance varied from 1994 to 1999: E-
resistance decreased from 18% to II % and T-resistance increased from 5%
to 17%. Out of61 E-rcsistant strains we found the following phenotypesf
genes: 43 with MfmefA; 8 with MLSBfermAM; 7 with inducible MLSBf
ermTR and 3 with erm + mef. E-resistant strains were also resistant to Azi,
CIa and Ro. Josamycin MIC were all S; 0.25 Ilgfml with the exception of
constitutive MLSB strains which had an MIC of ~8 ~ml.
Conduslons: We conclude that erythromycin resistance of S. pyogenes in
Austria has become infrequently and varies regionally; the M-resistant
phenotype is the most predominant;josamycin may constitute an alternative
for E-resistant strains with M-type; susceptibility testing is recommended for
situations in which macrolides are chosen.
P:5/9 - Quinolones
IWeP112! Bactericidal activity of ciprofloxacin and
levofJoxadn on 5. Pneumoniae at various phases of growth
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IWeP1 091 Susceptibility of Portuguese Haemophi/us
influenzae isolates to azythromydn. c1arithromycin and
erythromycin
M. P. Lavado. D. Louro, M. M. Cani~a
NIH Dr. Ricardojorge, Lisbon, Portugal
Objectives: To evaluate the comparative in vitro antibacterial activity of
three macrolides against portuguese clinical isolates of Haemophilus injluen-
zae (Hi).
Methods: MICs (agar dilution method, NCCLS, 1999) of azythromycin.
clarithromycin and erythromycin were determined against 150 isolates ofHi
(50 ,a-Iactamase producers, bl + 100 non ,a-Iaetamase producers. bl-). {3-
lactamase production was detected with nitrocefin. Strains. collected from
10 clinical laboratories. had the following characteristics: 97% - respiratory
tract, 79% - children; 92% - outpatients.
Results: MIC50 and MIC90 were as follow (mgfL):
100 Hi bl- 50 Hi b1+
MIC MIC
Antibiotic MIC50 MIC90 range MIC50 MIC90 range
Erythromycin 2 2 <0.06-8 2 4 1-4
Clarithromycin 2 4 :0;0.06-164 8 1-8
Azythromycin 0.25 0.5 :0;0.06-2 0.5 I 0.25-2
The rank order of activity on a weight basis was: azithromycin >
erythromycin ~ clarithromycin. For erythromycin 92% of strains were
classified as intermediate; 2 (I %) strains were resistant to this antibiotic. All
strains were susceptible to the other macrolides.{3-laetamase production did
not significantly influence the antimicrobial activity ofthe macrolides tested.
COnclusions: These results arc similar to the ones observed in other coun-
tries: azithromycin was fourfold more active than erythromycin, which was
slightly more active than clarithromycin. Erythromycin had poor activity
with a susceptibility rate of 7%. The newer macrolides are an interesting
alternative for therapy of Hi infections, since they showed to bc potent
agents against ampicillin resistant as well as ampicillin susceptible strains.
F. Scaglione. G. Demartini, S. Dugnani, F. Fraschini
Dept. ofPharmacology, University ofMilano, Italy
Streptococcus pneumoniae is a microorganism, which frequently colonizes the
upper respiratory tract. and represent an important cause of bacterial
pneumonia and meningitis. In the past pneumococci were found to be
extremely susceptible to both beta-Iaetam and macrolide antibiotics. How-
ever in the last decade there have been several reports of increased penicillin
resistance among pneumococcal strains isolated in several different countries.
New quinolones could represent a valid alternative in the therapy of
pneumococcal diseases. Previous study showed that old quinolones posses
different bactericidal effect at various phases of bacterial growth.
The aim of the study was to determine the bactericidal activity of
ciprofloxacin and levofloxacin against one recent clinical isolate ofpenicillin
resistant Streptococcus pneumoniae (MIC 2 mgfL). Time-kill studies were
performed over a 24 h period with sampling at 0, 4, 8 and 24 h. Isolates were
tested at a concentration oft X MIC.2 x MIC and 4 X MIC against bacteria
in logarithm growth phase and in stationary phase. Levofloxacin was found
to have an antibacterial activity comparable to that of ciprofloxacin against
bacteria in logarithm growth phase. Against bacteria in stationary phase.
levofloxacin showed a bactericidal effect (3-log reduction ofbacterial size) at
all concentrations tested, while ciprofloxacin was found bactericidal only at
the higher concentration. This data may support the hypothesis that several
mechanisms are involved in the concentration-dependent activity ofquino-
lones. Particularly the nucleic acid synthesis may play an important role.
IWeP1131 Susceptibility to moxifloxadn and other
antimicrobial agents of major pathogens responsible for
community acquired infections of respiratory tract
K. Betlejewska, M. Turzynska. W. Hryniewicz
Sera & Vaccines Central Research Laboratory, Warsaw, Poland
Objectives: To determine susceptibility to moxifloxacin and other anti-
microbial agents of major pathogens responsible for community acquired
respiratory tract infections.
Methods: Altogether 500 bacterial strains isolated in 1999 in different
regions of Poland from patients with upper (n 0; 223) and lowcr (n =
